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Immunization of Noncolonized Cystic Fibrosis Patients against Pseudomonas
aeruginosa
Stanley J. Cryz, Jr., Joanna Wedgwood, Alois B. Lang,
Anna Ruedeberg, J. U. Que, Emil Furer,
and Urs B. Schaad*
Swiss Serum and Vaccine Institute and Department of Pediatrics.
Inselspital. University ofBerne. Berne. Switzerland
The long-term safety and immunogenicity of a polyvalent Pseudomonas aeruginosa conjugate
vaccine was evaluated in 30 noncolonized cystic fibrosis patients. Four doses were administered
over 3 years, and patients were followed for a mean of 38 months. No acute or long-term adverse
effects were noted. Immunization engendered a significant antibody response to all vaccine com-
ponents. A decline in titers during year 3 of observation was associated with a marked rise in the
isolation of P. aeruginosa. This organism was isolated repeatedly from the respiratory tract of 4
patients and only once from 7 patients. The remaining patients were repeatedly culture-negative.
Only 1 patient showed clinical deterioration associatedwith multiple isolations of P. aeruginosa.
Pseudomonas aeruginosa is the leading cause of broncho-
pulmonary infection in patients with cystic fibrosis (CF) [1].
A substantial proportion of morbidity and mortality in this
patient population is the result of recurrent pulmonary exac-
erbations subsequent to colonization. Rarely can P. aerugin-
osa be eradicated through antibiotic treatment. Further com-
plicating treatment is the fact that multiply resistant strains
often arise after repeated or prolonged drug therapy or pro-
phylaxis.
Colonization of the lower respiratory tract by mucoid vari-
ants of P. aeruginosa is preceded by infection of the upper
respiratory tract by smooth strains [2]. Such natural exposure
to P. aeruginosa stimulates a vigorous humoral antibody re-
sponse to many somatic and extracellular antigens [3, 4].
However, such antibodies do not prevent or even ameliorate
subsequent infections. In fact, several laboratories [5, 6]
have noted a positive correlation between elevated anti-P
aeruginosa antibody titers and a more severe disease course.
This may be the result ofimmune complexes being deposited
in the lungs and other organs.
Anti-P. aeruginosa lipopolysaccharide (LPS) antibodies
acquired after natural exposure are not effective at promot-
ing opsonophagocytic killing [7]. We have found that anti-
P. aeruginosa LPS antibodies acquired subsequent to coloni-
zation had very low average affinity constants, which
Received 26 July 1993; revised 14 December 1993.
Written informed consent was obtained from patients or their guardians
prior to their enrollment in this study and subsequent to the review and
acceptance of the study by the Institutional Review Board of the Inselspital,
Berne.
Reprints or correspondence: Dr. S. J. Cryz, Jr., Swiss Serum and Vaccine
Institute. P.O. Box 2707. CH-3001 Berne. Switzerland.
* Present affiliation: Department of Pediatrics. University ofBasel. Basler
Kinderspital, Basel, Switzerland.
The Journal of Infectious Diseases 1994;169:1159-62
© 1994 by The University of Chicago. All rights reserved.
0022-1899/94/6905-0040$01.00
correlate with poor opsonic activity [8]. In contrast, vaccine-
induced antibodies are opsonic and of high affinity [8].
We have recently described the safety and immunogenic-
ity of a P. aeruginosa O-polysaccharide (O-PS)-toxin A con-
jugate vaccine in 22 young. noncolonized CF patients [9].
Vaccination resulted in a good antibody response and ex-
erted no obvious harmful effects on clinical status. However.
the comparatively short length of follow-up (mean, 18
months) did not allow firm conclusions regarding the effect
ofvaccination on the acquisition ofP. aeruginosa, long-term
clinical ramifications. and duration of antibody response.
These studies have been expanded to include 30 noncolon-
ized patients followed for an average of38 months after vacci-
nation. Various clinical. serologic, and bacteriologic parame-
ters were analyzed.
Materials and Methods
Over 31 months, 30 CF patients (13 males, 17 females) aged
1.6-24.0 years (mean, 8.3) were enrolled. All were in good
health and clinically stable and had no history of infection with
P. aeruginosa. On entry. sputum or throat swabs (or both) were
negative for P. aeruginosa.
Patients were immunized intramuscularly at O. 2, 12, and 36
months with a low (12.5 J.lg ofO-PS per serotype, n = 19) or a
high (25 J.lg of O-PS per serotype, n = 11) dose of octavalent
O-PS-toxin A conjugate vaccine [9] that contained the follow-
ing International Antigen Typing System (IATS) LPSserotypes:
1.2/5.3.4,6,7. 10, and 16. Patients were observed for 60 min
after immunization. For assessment of adverse reactions. report
forms were completed by the patient or parent for 96 h after
vaccination. Each patient was examined and interviewed ,...., 1
week after immunization. Venous blood samples were taken at
the time of each immunization and at 1- and 3-month intervals
thereafter. Blood chemistry profiles were analyzed at baseline
and 1 week after the first two immunizations. Disease severity,
recorded at the time of the initial immunization and at 12-
month intervals thereafter, was determined on the basis of spu-
tum and throat cultures collected at 3- to 6-month intervals ands
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Figure 1. Lipopolysaccharide IgG antibody response to A,
IATS-6: B. IATS-l I; C, IATS-I0; and D, toxin A. Each data point
represents geometric mean titer for all patients. Arrows indicate
immunization times.
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throat swabs or sputum cultures from 7 patients (23%) during
year I, from 2 during year 2, and from 4 during year 3. All 7
patients were culture-negative (6 by BAL) on subsequent
culturing (6-24 months of follow-up). Four patients had P.
aeruginosa isolated on two or more occasions. In the first
patient, P. aeruginosa was first isolated from sputum 33
months after primary immunization. A BAL sample taken 5
months later was also positive as were 7 subsequent sputum
or throat cultures taken over 10 months. This patient was
hospitalized (without exacerbation) and treated with intrave-
nous antibiotics in an attempt to eradicate P. aeruginosa,
which was ineffective. Changes in clinical scores were asso-
ciated with colonization (Chrispin-Norman score of5 at time
oand 7 at 36 months; Bernese score of24 at time 0 and 21 at
36 months). Significantly. only a 2- to 4-fold transient rise in
anti-LPS antibody titer was engendered by vaccination.
The second patient had P. aeruginosa isolated (BAL and
sputum) 13 months after immunization; four subsequent
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Results
About 43% ofvaccinations were associated with local reac-
tions characterized by pain, swelling, erythema, or a combi-
nation thereof. Such reactions were predominantly mild and
transient. Severity of reactions was not age-dependent and
did not increase with booster doses ofvaccine. There were no
systemic reactions of note nor any clinically significant
changes in blood chemistry parameters that could be attrib-
uted to immunization.
Because the magnitude and kinetics of the immune re-
sponse did not differ substantially between the two vaccine
dosages, the results were combined for ease ofanalysis. Rep-
resentative IgG antibody responses to three LPS serotypes
and to toxin A are shown in figure I. The two-dose primary
immunization schedule elicited a highly significant (P < .0 I)
rise in antibody titers to all nine vaccine components. Al-
though antibody levels declined, they were still significantly
(P < .05) higher than baseline at 12 months. A single booster
dose at this time evoked a pronounced rise in IgG antibody
levels. Anti-LPS titers subsequently declined so that by 24
months, they were no longer significantly above baseline.
Although antitoxin A antibody titers also fell, they remained
significantly (P < .01) above preimmunization levels at all
time points. A second booster dose at 36 months stimulated
a vigorous anti-LPS and antitoxin A antibody response with
peak titers achieved I month later. Again, antibody levels
rapidly declined over the subsequent 4 months but remained
significantly (P < .05) above baseline.
Before immunization, only 23% of patients possessed
toxin A-neutralizing antibodies (table I). Primary vaccina-
tion resulted in a > IO-fold rise in mean toxin A neutralizing
levels with 87%ofpatients seropositive. Neutralizing antibod-
ies were maintained by most patients throughout the study
with periodic boosters causing a significant (P < .0 I) rise in
neutralizing activity.
P. aeruginosawas never isolated from 19 (61%) of the im-
munized patients. P. aeruginosawas isolated only once from
by two scoring systems, the clinic Bernese CF score and the
Chrispin-Norman radiographic score [9]. Patients were followed
for a mean of 37.8 months (range, 20-46).
Total serum anti-LPS immunoglobulin G (IgG) antibody was
measured by ELISA [9]. The average affinity constants for such
antibodies were determined [8]. The ability ofsera to neutralize
the cytotoxicity of toxin A was determined in a HEp-2 cell assay
[9]. P. aeruginosa clinical isolates were serotyped by agglutina-
tion of whole bacteria using polyclonal typing sera (Public
Health Laboratory Service, London). Bronchoalveolar lavage
(BAL) was done on selected patients using an Olympus (Lake
Success, NY) bronchoscope. BAL fluid was plated directly onto
blood agar plates, and each bacterial colony type was identified
by standard laboratory techniques.
Significance of differences between antibody concentrations
at various time points was assessed with a paired t test.
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Discussion
Table 1. Toxin A-neutralizing antibody engendered by immuni-
zation.
NOTE. Patients were immunized at O. 2. 12.and 36 months. GM. geo-
metric mean.
* Limit of detection was 0.312 JIg neutralized/ml. of serum.
Colonization of the lower respiratory tract of CF patients
with P. aeruginosa may be viewed as a gradual, multistep
process influenced by several factors, including initial colon-
ization of the upper respiratory tract, translocation to the
lower respiratory tract, decreased mucociliary clearance, con-
comitant infection with other bacteria or viral pathogens, CF
transmembrane conductance regulator mutation genotype
[ 10], and a switch from a smooth to a mucoid phenotype.
Given these circumstances, preventing or even delaying the
acquisition ofP. aeruginosa could provide a substantial bene-
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fit to the patient. Attempts to achieve this goal with prophy-
lactically administered antibiotics have had a modest degree
of success [II].
A previous attempt to immunize noncolonized CF pa-
tients against P. aeruginosa did not influence the rate ofcolo-
nization [12]. Furthermore, there appeared to be a predispo-
sition to a more severe disease course once infection
occurred among the vaccinated group [12]. In contrast, we
have found that multiple immunizations with a polyvalent P.
aeruginosa vaccine over 3 years was not associated with any
identifiable adverse events other than local reactions at the
site of administration. The disease course did not appear to
be affected by vaccination as monitored by two scoring sys-
tems nor was there any evidence ofan immune complex-like
syndrome. Furthermore, while 4 immunized patients ap-
peared to become colonized or infected with P. aeruginosa
during the course of this study, they did not undergo an un-
usually rapid clinical deterioration.
Immunization engendered a significant rise in IgG anti-
body levels to all vaccine constituents. Interestingly, there
was a pronounced anamnestic response to booster doses ad-
ministered at 12 and 36 months, a phenomenon not seen in
healthy adult subjects [13]. However, there was a more rapid
drop-off in antibody titers after booster doses compared with
primary immunization. The kinetics and longevity of the im-
mune response would indicate that booster vaccinations
would be required at 12- to 18-month intervals to maintain
potentially protective antibody levels.
The current findings demonstrate that vaccination ofnon-
colonized CF patients with a polyvalent O-PS-toxin A con-
jugate vaccine was not associated with any identifiable risks.
We are now attempting to increase the immunogenicity of
this vaccine with novel adjuvants. On the basisofthese prom-
ising results, a double-blind placebo-controlled trial to evalu-
ate vaccine efficacy in noncolonized CF patients may be
warranted.
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cultures were negative. However, P. aeruginosa was again
cultured at 37 months from BAL fluid. This patient was hos-
pitalized (no exacerbation) after the second isolation of P.
aeruginosa for intravenous antibiotic treatment. Clinical
scores remained unchanged throughout the 42 months of
follow-up. After vaccination, a good (-- 10-fold rise) anti-
body response was mounted and maintained to the LPS sero-
type expressed by the infecting strain.
P. aeruginosa was first isolated from sputum of the third
patient 21 months after immunization, with a second isola-
tion at 24 months. Vaccination elicited a minimal «2-fold)
response to this serotype. Clinical scores remained essen-
tially unchanged.
P. aeruginosa was first isolated from the fourth patient 29
months after vaccination with a second isolation at 35
months. This patient mounted an excellent immune re-
sponse after vaccination and maintained titers significantly
above baseline levels. P. aeruginosa was not isolated from
this patient at a 6-month follow-up.
None of the P. aeruginosa strains isolated had a mucoid
phenotype. Four serotypes (IATS-2/5/16, IATS-4, IATS-5,
and IATS-ll) were identified. One strain was nontypeable.
IATS-il was not represented in the vaccine.
1162 Concise Communications lID 1994; 169 (May)
6. van Bever HP, Gigase PL, DeClerck LS. Bridts CH. Franckx H. Stevens
WJ. Immune complexes and Pseudomonas aeruginosa antibodies in
cystic fibrosis. Arch Dis Child 1988;63: 1222-8.
7. Eichler I, Joris L. Hsu YP. van Wye J. Bran R, Moss R. Nonopsonic
antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccha-
ride-specific immunoglobulin G antibodies from infected patient
sera inhibit neutrophil oxidative response. J Clin Invest 1989;84:
1794-804.
8. Bruderer U. Cryz SJ Jr. Schaad UB. Deusinger M, Que JU. Lang AB.
Affinity constants of naturally acquired and vaccine-induced anti-
Pseudomonas aeruginosa antibodies in healthy adults and cystic fi-
brosis patients. J Infect Dis 1992; 166:344-9.
9. Schaad UB. Lang AB. Wedgwood J, et al. Safety and irnmunogenicity
of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.
Lancet 1991;338:1236-7.
10. Kubesch P, Dark T, Wulbrand U, et al. Genetic determinants airways'
colonization with Pseudomonas aeruginosa in cystic fibrosis. Lancet
1993;341: 189-93.
II. Valerius NH. Koch C, Hoiby N. Prevention of chronic Pseudomonas
aeruginosa colonization in cystic fibrosis by early treatment. Lancet
1991 :338:725-6.
12. Longford DT. Hiller J. Prospective. controlled study of a polyvalent
Pseudomonas vaccine in cystic fibrosis: three year results. Arch Dis
Child 1984;59: J 13J-4.
13. Cryz SJ Jr, Sadoff JC, Fiirer E. Immunization with a Pseudomonas
aeruginosa immunotype 50-polysaccharide-toxin A conjugate vac-
cine: effect of a booster dose as antibody levels in humans. Infect
Immun 1988;56:1829-30.
Mutations in the Catalase-Peroxidase Gene from Isoniazid-Resistant
Mycobacterium tuberculosis Isolates
Manuel Altamirano, Johanna Marostenmaki,
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and John A. Smith
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Isoniazid resistance in Mycobacterium tuberculosis has been associated with total deletion of
the katG gene, which codes for catalase-peroxidase production. To determine whether this is a
common mechanism of drug resistance, 9 isolatesof isoniazid-resistant and 1 of isoniazid-sensi-
tive M. tuberculosis were analyzed by polymerase chain reaction amplification of a 237-bp se-
quence of the katG gene. Amplification was observed in the isoniazid-sensitive isolate and in 8
resistant isolates; in only 1 isoniazid-resistant isolate was there no amplification of the expected
band, suggesting gene deletion. DNA sequencing showed that 8 of the 9 isolates had point
mutations, deletions, or insertions of 1-3 bases. Evidencecorroborating the presence of muta-
tions in the katG gene was obtained by single-strand conformation polymorphism analysis in
these 8 isolates. Thus, mutations as well as insertions and deletions in the katG gene can account
for inactive catalase peroxidase, leading to isoniazid resistance; gene deletion occurs only infre-
quently, in -11% of cases.
Tuberculosis is still a problem worldwide. It is estimated
that one-third of the world's population is infected by Myco-
bacterium tuberculosis. Tuberculosis is among the most im-
portant infectious diseases, with 3 million deaths per year
[1]. Tuberculosis is a problem not only in developing coun-
tries: Industrialized countries have experienced a decline in
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tuberculosis, but since 1985 this trend has been reversed,
with increases of 18.4% in the United States to 33% in Swit-
zerland [2]. The increase in tuberculosis frequency in the
United States can be correlated with the AIDS epidemic, the
influx of infected immigrants. outbreaks of tuberculosis in
congregative facilities [3], and numbers of homeless [4]. To
complicate the problem, outbreaks ofmulti drug-resistant tu-
berculosis have been reported lately in 14 hospitals and in
the prison system, with documented cases ofmultidrug-res is-
tant tuberculosis in 241 patients and 15 health workers [5].
Drug resistance has been found in 60% of homeless persons
with tuberculosis in Boston, 21% in New York, and 27% in
San Antonio [4]. Also, there is a rapid spread of multidrug-
resistant tuberculosis, especially in human immunodefi-
ciency virus-infected patients. [6], who have a mortality rate
of ~89% [3]. This situation is reminiscent of the prechemo-
therapy age [7].
